Spectral MD Holdings, Ltd., a predictive analytics company, develops AI algorithms and optical technology in wound care treatment. The company is headquartered in Dallas, Texas.
| Revenue (TTM) | $15.39M |
| Gross Profit (TTM) | $6.61M |
| EBITDA | $-11.76M |
| Operating Margin | -122.70% |
| Return on Equity | -2308.00% |
| Return on Assets | -41.90% |
| Revenue/Share (TTM) | $0.51 |
| Book Value | $-0.38 |
| Price-to-Book | 26.08 |
| Price-to-Sales (TTM) | 3.28 |
| EV/Revenue | 3.41 |
| EV/EBITDA | -3.41 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -30.40% |
| Shares Outstanding | $32.18M |
| Float | $27.89M |
| % Insiders | 12.93% |
| % Institutions | 19.60% |
Volatility is currently contracting
DALLAS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Vincent Capone, Chief Executive Officer, and David McGuire, Chief Financial Officer, are scheduled to present at the H.C.
Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript
Company Continues to Advance Towards First Commercial Sales of the DeepView® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2026 (“Q2 2026”). “Spectral AI has entered the second half of 2026 with tremendous momentum and a clear sense of purpose,” said Vincent Capone, Chief Executive Officer of Spectral AI.
DALLAS, July 29, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the same day to discuss its financial results.
Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and Education
DALLAS, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the British Burn Association (BBA) Annual Conference, held on June 17th – 19th at the Nottingham Trent University, Nottingham, England. The Company's DeepView® System was on display and was the subject of multiple podium and poster presentations during the conference, highlighting its contributions to advancing burn care through advanced diagnostic analysis across the globe.
Company Will Showcase FDA-Cleared DeepView® System for Burn Indication Company Will Showcase FDA-Cleared DeepView® System for Burn Indication
DALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accomplishments to date and targeted milestones for 2026 following the receipt of De Novo Classification for its DeepView® System from the U.S. Food and Drug Administration (“FDA”).
DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView® System. With this classification, Spectral AI is authorized to commence commercial distribution activities in the United States.
Development Work for DeepView ® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on MDAI and any ticker you trade — then tracks every position and per-strategy win rate.
